检查点抑制剂在化疗难治性霍奇金淋巴瘤中多早可诱导完全代谢缓解?
一例24岁经典型霍奇金淋巴瘤患者,初治达代谢完全缓解(mCR)后失访,4年后复发为IVB期伴肝脾受累,两次肝功能调整的挽救治疗无效后启用帕博利珠单抗。因危及生命的状况错过治疗前PET,第+10天PET示接近mCR,第2周期前(第+21天)确认mCR,首次在文献中提示帕博利珠单抗可极早期达mCR。
要点
- 帕博利珠单抗治疗化疗难治性经典型霍奇金淋巴瘤,第+10天PET示接近mCR。
- 第2周期前(第+21天)确认mCR,为文献首次报道极早期mCR。
- 治疗前PET因危及生命的状况未进行。
核心结论
- 帕博利珠单抗可在化疗难治性经典型霍奇金淋巴瘤中极早期诱导mCR,为文献首次报道。
研究设计与样本
- 个案报道:1例24岁男性经典型霍奇金淋巴瘤患者。
主要发现
- 初治达mCR后失访,4年后出现B症状且临床状况恶化,诊断为复发经典型霍奇金淋巴瘤。
- PET/CT示IVB期,累及肝脏和脾脏。
- 两次肝功能调整的挽救治疗无效。
- 帕博利珠单抗治疗后临床逐渐改善;治疗前PET因危及生命的状况未进行。
- 第+10天PET示接近mCR,第2周期前(第+21天)确认mCR。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 24-year-old man with classical Hodgkin lymphoma was lost to follow-up after metabolic complete remission (mCR). He presented 4 years later with B-symptoms and impaired clinical condition. Relapsed classical Hodgkin lymphoma was diagnosed. PET/CT revealed stage IVB with liver and spleen involvement. Two liver function-adjusted salvage attempts were ineffective. Pembrolizumab was instituted with gradual clinical improvement. PET was missed before treatment for a life-threatening condition and was performed on day +10 showing a near mCR. A mCR was confirmed before cycle 2, on day +21, underlining-for the first time in the literature-the possibility to achieve very early mCR with pembrolizumab.
引用
- Georgopoulou AN, Zerzi C, Samaras V, et al. How Early Can Checkpoint Inhibitors Induce a Complete Metabolic Response in Chemorefractory Hodgkin Lymphoma? Clin Nucl Med. 2024. PMID: 38350084. doi:10.1097/RLU.0000000000005070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。